Search Results - "FAULHABER, José Claudio"

Continuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide data by Paula, Adelzon A, Schechter, Mauro, Tuboi, Suely H, Faulhaber, José Claudio, Luz, Paula M, Veloso, Valdiléa G, Moreira, Ronaldo I, Grinsztejn, Beatriz, Harrison, Lee H, Pacheco, Antonio G

“…After antiretroviral therapy (ART) became available, there was a decline in the number of deaths in persons infected with HIV. Thereafter, there was a decrease…”
Get full text

Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil by Pacheco, Antonio G, Saraceni, Valeria, Tuboi, Suely H, Lauria, Lilian M, Moulton, Lawrence H, Faulhaber, José Cláudio, King, Bonnie, Golub, Jonathan E, Durovni, Betina, Cavalcante, Solange, Harrison, Lee H, Chaisson, Richard E, Schechter, Mauro

“…Non-HIV-related causes of death have been increasing after the introduction of highly active antiretroviral therapy. Underlying and contributing causes of…”
Get more information

Viral Load and CD4 Count Dynamics After HIV-1 Seroconversion in Homosexual and Bisexual Men in Rio de Janeiro, Brazil by Djomand, Gaston, Duerr, Ann, Faulhaber, José Cláudio, Struchiner, Claudio J, Pacheco, A Guilherme, Barroso, Paulo F, Melo, M Fatima, Schechter, Mauro

“…PURPOSE:Reliable predictors of HIV disease progression are scarce in developing countries, where most HIV infections occur. We describe early virologic and…”
Get full text

Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts by Schechter, Mauro, Zajdenverg, Roberto, Falco, Gisely, Barnes, Grace Link, Faulhaber, Jose Claudio, Coberly, Jacqueline S, Moore, Richard D, Chaisson, Richard E

“…Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies. To compare…”
Get full text

Barriers to Recruit Female Commercial Sex Workers for HIV Vaccine Trials: The Rio de Janeiro Experience by Barroso, Paulo Feijó, de Souza, Monica Barbosa, do Lago, Regina Ferro, Pedrosa, Jorge, Yoshida, Carina Beppu, Faulhaber, José Cláudio, Costa, Marcellus Dias, Schechter, Mauro

Get full text

Weekly rifapentine/lsoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts by SCHECHTER, Mauro, ZAJDENVERG, Roberto, FALCO, Gisely, BARNES, Grace Link, FAULHABER, José Claudio, COBERLY, Jacqueline S, MOORE, Richard D, CHAISSON, Richard E

Get full text

Identification of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil, using a sensitive/less-sensitive assay: an update by Barroso, Paulo Feijó, Harrison, Lee H, de Fátima Melo, Maria, Batista, Sônia Maria, da Silva Bastos, Marilene, da Rosa Faulhaber, José Claudio, Moreira, Ronaldo Ismério, do Lago, Regina Ferro, Schechter, Mauro

Get full text

Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil by SCHECHTER, M, DO LAGO, R. F, DE MELO, M. F, SHEPPARD, H. W, GUIMARAES, N. C, MOREIRA, R. I, FAULHABER, J. C, BATISTA, S, HARRISON, L. H

“…Schechter et al have identified a heterosexual population in Rio De Janeiro with a high rate of HIV transmission willing to participate in placebo-controlled…”
Get full text

Brief Report: Identification of a High-Risk Heterosexual Population for HIV Prevention Trials in Rio de Janeiro, Brazil by Schechter, Mauro, do Lago, Regina F., de Melo, Maria Fátima, Sheppard, Haynes W., Guimarães, Nelson C., Moreira, Ronaldo Ismério, Faulhaber, José Claudio, Batista, Sonia, Harrison, Lee H.

Get full text

Brief Report: Identification of a High-Risk Heterosexual Population for HIV Prevention Trials in Rio de Janeiro, Brazil by Schechter, Mauro, do Lago, Regina F, de Melo, Maria Fátima, Sheppard, Haynes W, Guimarães, Nelson C, Moreira, Ronaldo Ismério, Faulhaber, José Claudio, Batista, Sonia, Harrison, Lee H

“…The study of interventions to prevent HIV transmission requires access to populations with a high rate of HIV transmission. We estimated HIV incidence among…”
Get full text

Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study) by Nunes, Estevão P, Santini de Oliveira, Marilia, Merçon, Monica, Zajdenverg, Roberto, Faulhaber, Jose Claudio, Pilotto, José Henrique, Ribeiro, Jorge Eurico, Norton, Michael, Schechter, Mauro

“…Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to…”
Get more information